HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Soon J. Park Roque Pifarré Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Walenga, J. M. Articles by Pifarré, R. Search for Related Content PubMed PubMed Citation Articles by Walenga, J. M. Articles by Pifarré, R.

Ann Thorac Surg 1994;58:1685-1689
© 1994 The Society of Thoracic Surgeons

---

Articles

Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model

Department of Thoracic and Cardiovascular Surgery, Lovola University Medical Center, Maywood, Illinois USA

Accepted for publication June 1, 1994.

^_* Address reprint requests to Dr Walenga, Department of Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL 60153.

Recombinant desulphatohirudin HV1 (CGP 39393), a specific and potent peptidic inhibitor of thrombin, was evaluated as the sole anticoagulant in a dog model of cardiopulmonary bypass. CGP 39393 was administered as a bolus plus infusion for a 1-hour pump period at doses of 1.0 mg/kg + 0.75 mg·kg^–1.h^–1, 1.0 mg/kg + 1.50 mg · kg^–1 · h^–1, 1.0 mg/kg + 225 mg · kg^–1 · h^–1, or 1.0 mg/kg + 3.0 mg · kg^–1 · h^–1 (n = 5 per group). The lowest dose was ineffective, as a high degree of clot formation (314 ± 160 mg) occurred as determined by quantitation of protein deposits in the pump line filter. The three higher doses inhibited clot formation (35 to 44 mg) but did not reveal a dose-dependent effect (p = 0.308 between groups). All four doses produced the same amount of postoperative blood loss (6.5 to 10 g/kg over 2 hours; p = 0.215 between groups) and no oozing of blood from cut tissues (sternum, muscle, skin) during or after operation. No adverse hemodynamic or hematologie effeds were observed. Animals were physiologically stable coming off pump, requiring minimal fluid replacement or other cardiovascular supportive measures. The chromogenic anti-lla assay could be used to monitor CGP 39393. Same activated partial thromboplastin time and all activated clotting time values were off scale on pump, but they fell immediately after cardiopulmonary bypass, typicalty reaching near-normal levels within 30 to 60 minutes. No reversal of CGP 39393 was used, as blood levels declined rapidly after cessation of the infusion. This stady in 2 dog model shows that CGP 39393 administered as a bolus plus infusion (minimum dose, 1.0 mg/kg + 1.50 mg · kg^–1 · h^–1) can be used safely and effectively during cardiopulmonary bypass for cardiac operation.

This article has been cited by other articles:

				F. Follis and C. A. Schmidt Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis Ann. Thorac. Surg., December 1, 2000; 70(6): 2173 - 2181. [Abstract] [Full Text] [PDF]

				T. B. Spanier, M. C. Oz, O. P. Minanov, R. Simantov, W. Kisiel, D. M. Stern, E. A. Rose, and A. M. Schmidt Heparinless cardiopulmonary bypass with active-site blocked factorIXa: A preliminary study on the dog J. Thorac. Cardiovasc. Surg., May 1, 1998; 115(5): 1179 - 1188. [Abstract] [Full Text] [PDF]

				M. R. Terrell, J. M. Walenga, M. J. Koza, and R. Pifarre Efficacy of Aprotinin With Various Anticoagulant Agents in Cardiopulmonary Bypass Ann. Thorac. Surg., August 1, 1996; 62(2): 506 - 511. [Abstract] [Full Text]